Category: Pfizer

Full-Time Administration Defense Government Human Resources Manufacturing QA-Quality Control Research Science Overview We are seeking a Bioinformatics Scientist to support the National Institutes of Health’s National Institute of Allergy and Infectious Diseases’ (NIAID) Vaccine Immunology Program in Bethesda, MD. Our NIAID professional, technical, and scientific support personnel are part of…

An improvement in minimal residual disease (MRD)-negative complete remission (CR) rate was observed with ponatinib (Iclusig) plus reduced-intensity chemotherapy vs imatinib (Gleevec) plus reduced-intensity chemotherapy in newly diagnosed patients with Philadelphia chromosome (Ph)–positive acute lymphoblastic leukemia (ALL). Findings come from the phase 3 PhALLCON trial (NCT03589326) which were presented at…

PRESS RELEASE Published June 9, 2023 The Latest Research Report on Fanconi Anemia Market 2023 covering the micro level of analysis by competitors and key business segments. The Global Fanconi Anemia explores an inclusive study on various segments like growth drivers, opportunities, market size, shares, development, innovation, sales, and overall…

PRESS RELEASE Published June 8, 2023 Biotechnology is the application of scientific and engineering principles to the processing of materials by biological agents to provide goods and services. Today, biotechnology is being used to create new and improved crop varieties, develop renewable fuels, and create new industrial and consumer products….

Funding Support and Acknowledgements: COPDGene: The project described was supported by Award Number U01 HL089897 and Award Number U01 HL089856 from the National Heart, Lung, and Blood Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung,…

Novavax’s updated COVID-19 vaccine candidate is likely to protect against circulating omicron variants, according to a company official. Filip Dubovsky, the company’s head of research and development, said that the shot targets the currently dominant XBB.1.5 but that it should provide protection against other strains circulating. He told Reuters that…

The Importance Of Biotech And Healthcare Biotech and healthcare are massive parts of our economy. They are also literally vital to us whenever our bodies suffer from injuries, diseases, or other medical issues. It is also a sector driven by innovation and precious IPs, where thriving for new and improved…

(Adds Moderna’s comments on potential to seek accelerated approval in paragraphs 2-3, Phase 3 confirmatory study in paragraph 8) By Julie Steenhuysen CHICAGO, June 5 (Reuters) – Adding an experimental mRNA-based vaccine from Moderna Inc and Merck & Co reduced the risk that the most deadly skin cancer would spread…

Oncopole, Fonds de recherche du Québec – Santé (FRQS) cancer division in Canada, has received major investments that boost its public-private partnership model dedicated to the fight against cancer.  Oncopole will continue to pursue its mission thanks to a $3 million reinvestment from founding partner Merck Canada. Oncopole, FRQS cancer…

GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by developing pioneering technology to detect and identify multiple deadly cancer types early. The company is using the power of next-generation sequencing, population-scale…

No Peer Review Did a legitimate, peer-reviewed study successfully demonstrate that COVID-19 mRNA vaccines produced by Pfizer and Moderna were shown to contain simian virus 40 (SV40), a DNA virus that has been linked to certain cancers? No, that’s not true: The research in question was not published in a…

In late May I had the honor of speaking with Sucharit Bhakdi, MD regarding dsDNA contamination in the vaccines. First, we need to do some numbers. The 100ug Moderna shots deliver over 40 trillion mRNA molecules (14T for Pfizer) and the number of LNPs per shot is reported to be…

[1/2] Signage is seen at the Merck & Co. headquarters in Kenilworth, New Jersey, U.S., November 13, 2021. REUTERS/Andrew Kelly/File Photo CHICAGO, June 5 (Reuters) – Adding an experimental mRNA-based vaccine from Moderna Inc (MRNA.O) and Merck & Co (MRK.N) reduced the risk that the most deadly skin cancer would…

Emergence of a novel BA.1 sublineage through intrahost evolution We performed genomic analysis of serially collected nasopharyngeal (NP) and anterior nares (AN) samples from an immunocompromised patient (P1) with diffuse B-cell lymphoma and persistent SARS-CoV-2 Omicron BA.1 replication between December 2021 and March 2022. Over a 12-week period, we documented…

PRESS RELEASE Published June 2, 2023 Newark, New Castle, USA new report, titled Restriction Endonuclease Products Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Restriction Endonuclease Products market. Analysts have used a top-down and bottom-up approach…

Thomas Lohnes/Getty Images News BioNTech (NASDAQ:BNTX) reported promising data from a mid-stage clinical study for its therapy candidate BNT316/ONC-392 in the treatment of metastatic non-small cell lung cancer, or NSCLC, the most prevalent form of the disease. The German biotech company said preliminary data from a Phase 1/2 study showed…

BNT316/ONC-392 is a next-generation anti-CTLA-4 monoclonal antibody candidate jointly developed by BioNTech and OncoC4 as monotherapy or combination therapy in a range of solid tumor indications, including non-small cell lung cancer (NSCLC) Interim data of BNT316/ONC-392 from the ongoing Phase 1/2 trial to be presented at this year’s…

MT Newswires 2023 All news about PFIZER, INC. Analyst Recommendations on PFIZER, INC. Sales 2023 68 144 M – – Net income 2023 15 325 M – – Net Debt 2023 2 301 M – – P/E ratio 2023 13,8x Yield 2023 4,37% Capitalization 215 B 215 B – EV / Sales 2023 3,18x…

MANNHEIM, Germany — A novel drug that targets production of a liver protein involved in lipid metabolism appears to markedly reduce low-density lipoprotein (LDL) cholesterol levels for patients with homozygous familial hypercholesterolemia (HoFH), suggest results from the phase 2 GATEWAY trial. The research was presented at the European Atherosclerosis Society…

Pfizer has announced positive phase 3 results supporting the safety and efficacy of its investigational antibiotic combination, aztreonam-avibactam (ATM-AVI), in treating serious infections caused by multi-drug resistant, gram-negative bacteria. Declared by the World Health Organization as one of the top ten threats to global health, antimicrobial resistance occurs when bacteria,…

Data support that antibiotic aztreonam-avibactam (ATM-AVI) is effective and well-tolerated in treating infections caused by Gram-negative bacteria, with a similar safety profile to aztreonam alone NEW YORK–(BUSINESS WIRE)– Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 program comprising the REVISIT (NCT03329092) and ASSEMBLE (NCT03580044) studies evaluating…

The investigational antibiotic combination aztreonam-avibactam was found to be effective for treating serious bacterial infections caused by Gram-negative bacteria, according to findings from two phase 3 studies. The REVIST (ClinicalTrials.gov Identifier: NCT03329092) and ASSEMBLE (ClinicalTrials.gov Identifier: NCT03580044) studies were conducted to evaluate the efficacy and safety of the novel antibiotic…

Pfizer received approval from the FDA for ABRYSVO (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F (RSVpreF) vaccine, for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years and older. ABRYSVO is unadjuvanted and composed of two preF proteins selected to optimize protection…

Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 program comprising the REVISIT (NCT03329092) and ASSEMBLE (NCT03580044) studies evaluating the efficacy, safety, and tolerability of the novel investigational antibiotic combination aztreonam-avibactam (ATM-AVI) in treating serious bacterial infections due to Gram-negative bacteria, including metallo-β-lactamase (MBL)-producing multidrug-resistant pathogens for…

By Colin Kellaher Pfizer on Thursday reported positive results from a pair of Phase 3 studies evaluating the efficacy, safety and tolerability of the novel investigational antibiotic combination aztreonam-avibactam, or ATM-AVI. The New York drugmaker, which is studying the combination in the treatment of serious bacterial infections due to antibiotic-resistant…

Weekly treatment with the experimental therapy marstacimab (PF-06741086) was found to significantly reduce bleed rates for adult and adolescent hemophilia A and B patients without inhibitors relative to standard therapies. In so doing, it met the main goal of the pivotal Phase 3 BASIS clinical trial, designed to evaluate the…

Data Bridge Market Research announces the release of the report “Mild Cognitive Impairment (MCI) Treatment Market Size, Share, Growth & Trends Analysis Report By Product, By End Use, By Region And Segment Forecasts”. An excellent Mild Cognitive Impairment (MCI) Treatment market document concentrates on the global key manufacturers to define,…

Positive results in a late-stage clinical trial put Pfizer’s marstacimab in a position to become the first weekly injectable for patients with hemophilia B, the drugmaker said Tuesday.  If approved, the monoclonal antibody would also pose fresh competition to Roche and Sanofi in hemophilia A, although to what extent is…

SINGAPORE – A vaccine for the Nipah virus could be on the horizon, thanks to research on a new vaccine technology. Vaccine research organisation Hilleman Laboratories has announced a collaboration with the Agency for Science, Technology and Research (A*Star) to study the use of novel circular ribonucleic acid (circRNA) technology…

Jeenah Moon/Getty Images News Pfizer (NYSE:PFE) announced Tuesday that a pivotal Phase 3 trial for marstacimab, a candidate targeted at certain hemophilia patients as a prophylactic regimen, reached its primary endpoints. The global study involving about 145 adolescent and adult participants was designed to evaluate the annualized bleed rate through…

MT Newswires 2023 All news about PFIZER, INC. Analyst Recommendations on PFIZER, INC. Sales 2023 68 143 M – – Net income 2023 15 325 M – – Net Debt 2023 2 301 M – – P/E ratio 2023 13,6x Yield 2023 4,42% Capitalization 212 B 212 B – EV / Sales 2023 3,15x…

Study demonstrates statistically significant and clinically relevant reduction in annualized bleeding rate compared to prophylaxis and on-demand intravenous regimens Marstacimab, if approved, has the potential to become the first once-weekly subcutaneous treatment for people living with hemophilia B and the first treatment administered as a flat dose for people living…

© Reuters Pfizer Inc. (NYSE:) today announced that the pivotal Phase 3 BASIS clinical trial (NCT03938792) evaluating marstacimab has met its primary endpoints, having demonstrated statically significant and clinically meaningful effects. Marstacimab, a novel, investigational anti-tissue factor pathway inhibitor (anti-TFPI) being studied for the treatment of hemophilia A or B…

By Sharvari Rale, Fairfield Market Research The quest for the most effective disease treatments has become more urgent than ever. The global chronic disease burden is swelling at alarming rates, pointing to growing severity of the situation for the global healthcare system, economy, and public health. Prevalence of chronic conditions…

Programming note: We’ll be off this Monday for Memorial Day but will be back in your inboxes on Wednesday. The FDA granted full approval to Pfizer’s Paxlovid on Thursday. | Getty Images PAXLOVID FULLY APPROVED — The FDA on Thursday approved Covid-19 treatment Paxlovid for adults at high risk of…

Lyme disease is the most common vector-borne disease in the U.S. – a new CDC estimate suggests that approximately 476,000 Americans are diagnosed with Lyme disease each year – and it is caused by the bacterium Borrelia burgdorferi. It is primarily transmitted to humans through the bite of an infected…

The UKB is approved by the North West Multi-centre Research Ethics Committee (www.ukbiobank.ac.uk/learn-more-about-uk-biobank/about-us/ethics). The current study was conducted under UKB application no. 26041. The data in the UKB were collected after written informed consent was obtained from all participants. The Human Research Committee of the MGB approved the Biobank research…

In an uncertain economic environment, biotechnology stocks have been outpacing the overall stock market. However, Morningstar analysts say there are still undervalued stocks in this innovative industry. Among the biotech stocks trading at attractive prices are prominent names such as Moderna MRNA, which was in the spotlight for its COVID-19…

By Niomi Peckham, director, biologics pipeline development, Science-Global Biologics, United States Pharmacopeia The therapeutic potential of monoclonal antibodies (mAbs) came to the fore in the early 1970s when it was first demonstrated that pure protein could be obtained by fusing myeloma cells with the spleen cells of a mouse immunized…

Product Code Does a number code printed on a streetlight match that of a ribosomal protein and does this show that mRNA from the COVID-19 vaccines can be activated using optogenetic technology if a vaccinated person is exposed to the light from the street lamp? No, that’s not true: The…

A new drug may be on the horizon to help people kick the world’s deadliest habit. Achieve Life Sciences, Inc., a Seattle, Washington-based pharmaceutical company, has announced positive results from the Phase 3 trial of a drug called cytisinicline. Smoking claims more than seven million lives each year worldwide, making…

24K-Production Shares of small molecule developer Fulcrum Therapeutics (NASDAQ:FULC) have lost more than 80% of their value since the IPO was priced at $19 in August 2021. Year to date performance is negative 50% after FTX-6058 for sickle cell disease was placed on full clinical hold by the FDA in…

A new drug may be on the horizon to help people kick the world’s deadliest habit. Achieve Life Sciences, Inc., a Seattle, Washington-based pharmaceutical company, has announced positive results from the Phase 3 trial of a drug called cytisinicline. Smoking claims more than seven million lives each year worldwide, making…

Key highlights: Touchlight completes expansion of its UK manufacturing facility, tripling its production capacity to meet the growing global demand for DNA in genetic medicine treatments. Touchlight’s proprietary dbDNA technology enables rapid and scalable manufacturing of GMP DNA, overcoming technical challenges associated with large-scale plasmid DNA production. Touchlight has…

urbazon/E+ via Getty Images Life is what happens to us while we are making other plans.” – Allen Saunders. Today, we revisit Fate Therapeutics, Inc. (NASDAQ:FATE). This is a name I have not taken an in-depth look at in years but comes up from time to time on Live Chat….

Pfizer PFE published solid and detailed phase 2 data on diabetes and weight loss drug danuglipron largely in line with our expectations. We don’t expect any major changes to our fair value estimate or moat rating based on the data. If a larger phase 3 program continues to support a…

South Korean bio-venture Cellid Co. announced on Tuesday that it has applied for the clinical Phase 3 trial of the COVID-19 Omicron variant-specific vaccine, “AdCLD-CoV19-1 OMI,” to the Ministry of Food and Drug Safety. The Phase 3 trial will involve a target group of 4,000 adults aged 19 or older…

Global Biotechnology Market Size & Share to Surpass $2772.7 Billion by 2030 | Vantage Market Research WASHINGTON, May 22, 2023 (GLOBE NEWSWIRE) — The Global Biotechnology Market is valued at USD 1094.6 Billion in 2022 and is projected to reach a value of USD 2772.7 Billion by 2030 at a…

GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by developing pioneering technology to detect and identify multiple deadly cancer types early. The company is using the power of next-generation sequencing, population-scale…

asbe I covered Beam Therapeutics (NASDAQ:BEAM) in April last year, when the stock had a market cap of $3.7bn. Today, despite some derisking events, it has a market cap of $2.6bn. The stock price has fallen 30% as well. Co-founded by David Liu, the Broad Institute and Harvard biochemist who…

Technology in the service of health; And it is that Google launches AI solutions for drug research. The folks at Mountain View announced that they’re adding two new tools to their portfolio through Google Cloud to accelerate accurate medical searches. Its objective is that companies in biotechnology, pharmaceutical and public…

The positive vote is based on compelling scientific evidence presented, including Phase 3 efficacy and safety data in pregnant individuals and their infants FDA decision expected in August 2023 If authorized, the vaccine candidate would help protect infants at first breath through six months of life against RSV disease and…

Enzymatic DNA Synthesis Market The “Enzymatic DNA Synthesis Market” value is projected to reach US$ 2,244.88 million by 2028 from US$ 240.96 million in 2022; it is estimated to record a CAGR of 45.1% from 2022 to 2028. The rising prevalence of genetic disorders and the surging number of product…

Google Cloud has announced two new AI-powered life sciences solutions to accelerate drug discovery and precision medicine for biotech companies, pharmaceutical firms, and public sector organizations.  The Target and Lead Identification Suite helps researchers better identify the function of amino acids and predict the structure of proteins; and the Multiomics…

A large number of pharmaceutical companies are now utilizing AI to develop drugs. Google Cloud has unveiled two new suites of AI tools that aim to help the pharmaceutical industry accelerate drug discovery and make it cheaper. The suites, called Target and Lead Identification Suite and Multiomics Suite, leverage Google’s…

On May 17, 2023, AstraZeneca announced positive findings from the Phase 3 FLAURA2 trial of Tagrisso (osimertinib) combined with chemotherapy for locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor mutations. The study demonstrated that Tagrisso and chemotherapy together resulted in a significant improvement in…

The way drugs are developed is being rewritten as we speak. Discovering and approving new drugs is a lengthy process that requires years of development and a dismal success rate, but artificial intelligence (AI) could rev up the process in a major way. On May 15, Google Cloud launched two…

Pfizer and Colossal Biosciences are among the biotech and pharma firms already using two new suites of artificial intelligence tools unveiled this week by Google Cloud. WHY IT MATTERSThe new technologies, announced for general availability Tuesday at the Bio-IT World Conference & Expo in Boston, are designed to help organizations…

Credit: Aleksandra Krolik / EMBL Looking to deepen its services to the pharmaceutical and biotech industry, Google Cloud announced Tuesday at Bio-IT World Conference in Boston, the debut of two AI-powered research suites—one for target and lead identification and another multiomics. The Target and Lead Identification Suite will help researchers…

Google Cloud has announced two new AI-powered tools to help pharmaceutical and biotech companies accelerate new drug discovery and advance precision medicine. The first of these tools is the Target and Lead Identification Suite. It has been developed to make it easier for companies to predict and understand the structure…

Best known for its folklore and tales of the Vikings, Norway’s landscape boasts postcard-like islands and the northern lights. In addition to ranking top as one of the happiest nations in the world, the country relies on sectors like oil and gas, hydropower and aquaculture to strengthen its economic growth….

PITTSBURGH, May 16, 2023 (GLOBE NEWSWIRE) — NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing Stealth Editors™ to perform in vivo gene editing without triggering the immune system, today announced the formation of a gene editing advisory board comprised of distinguished leaders of the scientific community…

SHANGHAI, May 17, 2023 /PRNewswire/ — Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced today the completion of patient enrollment in a multi-center Phase 3 clinical trial of etrasimod in Asia for the treatment…

SHANGHAI, May 16, 2023 /PRNewswire/ — Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced today the completion of patient enrollment in a multi-center Phase 3 clinical trial of etrasimod in Asia for the treatment…

Several new clinical trials in breast cancer have opened in recent months. Maybe one of your patients could benefit from enrolling. Locally advanced unresectable or metastatic HR-positive, HER2-negative, PIK3CA-mutated breast cancer. Adults with this type of breast cancer whose disease has progressed despite treatment with a cyclin-dependent kinase 4/6 inhibitor…

Cerevel and Pfizer are using the Target and Lead Identification Suite—and Colossal Biosciences is adopting the Multiomics Suite—to bring therapeutics to market faster BOSTON, May 16, 2023 /PRNewswire/ — Today at the Bio-IT World Conference, Google Cloud announced two new AI-powered life sciences solutions to accelerate drug discovery and precision…

A person walks next to the Google Cloud logo at the Mobile World Congress (MWC) in Barcelona, Spain February 27, 2023. Nacho Doce | Reuters Google Cloud on Tuesday launched two new AI-powered tools that aim to help biotech and pharmaceutical companies accelerate drug discovery and advance precision medicine.  One…

“Stratagem Market Insights offers a 70% discount on Molecular Pharming Market Reports on Single User Access and Unlimited User Access“ The Molecular Pharming Market research study is a professional report with premium insights into the size of the business, current patterns, drivers, risks, potential outcomes, and major segments. The Industry…

17 Photo by Jeyaratnam Caniceus from Pixabay L’World Health Organization (OMS) declared the health emergency linked to COVID-19 over. This announcement, widely awaited based on the trend of infections, hospitalizations and deaths around the world, represents an important step towards normality and takes place more than three years after WHO…

In groundbreaking research, BioNTech is developing a personalized vaccine to treat pancreatic cancer, considered one of the deadliest in the world, with a case fatality rate of 88%. According to an article published in the journal Nature on Wednesday May 10, this experimental vaccine could stimulate the T cells of…

A personalized cancer vaccine made by BioNTech, the German company that produced the Pfizer-BioNTech COVID-19 vaccine, has shown promising results against pancreatic cancer. The vaccine, which teaches patients’ immune systems to attack their tumors, provoked an immune response in half of the 16 patients treated, and those patients did not…

ENGINEERING Tall wood building is shaken, but not scathed A 10-story wooden building survived two severe, simulated earthquakes intact this week as scientists sought to show that wood can rival steel and concrete to safely support tall buildings. The structure is the tallest ever tested at the University of California,…

A customized messenger RNA (mRNA) vaccine plus a checkpoint inhibitor and chemotherapy boosted T-cell immune responses in half of people who had received surgery for pancreatic cancer, according to a report this week in Nature. Although the study was small, these findings suggest that the vaccine may help prevent disease…

The sellside expects a bumper year for blockbuster approvals, a recent Evaluate Vantage analysis revealed, but which products are creating all the excitement? A handful of significant new agents have already been approved, in Alzheimer’s disease, geographic atrophy and respiratory syncytial virus, and there is no shortage of pending regulatory…

PRESS RELEASE Published May 11, 2023 Biotechnology is the application of scientific and engineering principles to the processing of materials by biological agents to provide goods and services. Today, biotechnology is being used to create new and improved crop varieties, develop renewable fuels, and create new industrial and consumer products….

PRESS RELEASE Published May 11, 2023 Newark, New Castle, USA Restriction Endonuclease Products Market Analysis 2023 | Business Opportunities, Pricing Strategy, Forthcoming opportunities planning, Market-specific challenges, Globally Market Key Facts are coverd in this report by Growth Plus Reports | 100+ Report Pages Restriction Endonuclease Products Market 2023 with 100+…

Experts have called for further scrutiny of a new Pfizer vaccine given during pregnancy to prevent respiratory infection in infants, after trials of a similar GSK vaccine were stopped after  a rise in preterm birth and infant deaths. Pfizer says its vaccine is safe and effective, but experts contacted as part…

PRESS RELEASE Published May 10, 2023 (Las Vegas, Nevada, USA) DelveInsight’s “Diabetes Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Diabetes, historical and forecasted epidemiology as well as the Diabetes market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan….

Drug Metabolizing Enzyme Market to Register a Steady Revenue CAGR of 7.4% by 2031 | Growth Plus Reports Newark, New Castle, USA, May 08, 2023 (GLOBE NEWSWIRE) — Growth Plus Reports estimated the size of the global market for drug metabolizing enzymes in 2022 and is expected to increase at…

Slowing demand for Covid-19 vaccines has caused BioNTech a massive profit slump. However, the Mainz-based company has some mRNA vaccines against cancer in the pipeline. Unsurprisingly, the vaccine manufacturer BioNTech was not able to build on the fabulous results of the corona pandemic in the first quarter. In a year-on-year…

Harvard University Professor David Liu, Ph.D. Juliana Sohn In the world of biotechnology, few innovations have generated as much excitement and promise as gene editing. With the advent of technologies such as CRISPR/Cas9, researchers are unlocking new frontiers in widespread disciplines ranging from agriculture to medicine. One of the pioneering…

Commercial-state biotechnology company ImmunoGen Inc. NASDAQ: IMGN shares more than doubled on phase 3 clinical trial results. Its ovarian cancer drug Elahere shows statistical improvements for progression-free survival (PFS) and overall survival (OS) for patients in a MIRASOL late-stage study. The PFS is the length of time a cancer patient…

The global CRISPR Nucleases Market research report gives point to point breakdown along with the data of CRISPR Nucleases market analytical study, regional analysis, growth factors and leading companies. The research report about the market provides the data about the aspects which drive the expansion of industry. The CRISPR Nucleases…

CHICAGO — A novel approach to revitalizing the duodenal mucosa as a means to restore normal insulin sensitivity in people with type 2 diabetes is showing strong promise in early studies, according to results presented here. In two single-arm trials of a system called ReCET, reported at Digestive Disease Week…

Yahoo Finance published this video item, entitled “Why the human genome could be health care’s holy grail” – below is their description. #youtube #stockmarket #genetics 23andMe Co-founder & CEO Anne Wojcicki says we’ve only seen the tip of the iceberg for human genomics and DNA research. “Look at all the…

Introduction Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma [1]. Based on gene expression profiling, DLBCL can be classified into two main subtypes: germinal center B-cell-like (GCB) and activated B-cell-like (ABC) [1]. The ABC subtype of DLBCL has particularly poor clinical outcomes with standard treatment…

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. And our agenda is quite busy. We are returning to the campus after a stint on the road, but then…

Codexis, Inc. CDX-7108 Clinical Development Program Remains on Track       Estimated Cash Runway Through End of 2024 Funds Important Upcoming Milestones Company Reiterates 2023 Total Revenue Guidance with Adjustments to Product vs. R&D Revenue Mix and Range on Gross Margin REDWOOD CITY, Calif., May 04, 2023 (GLOBE NEWSWIRE) —…

Elucidata’s mission is to power drug discovery by harnessing the power of structured and unstructured biomedical data. Our state-of-the-art technology transforms data so that it is analysis-ready. Biomedical data is vast but unstandardized, hence it remains underutilized. Or as we say available is not usable. Our platform, Polly, has been…

vadimrysev Investment Overview ImmunoGen (NASDAQ:IMGN) – an under the radar, Waltham, Massachusetts based biotech founded in 1981 sent its shareholders into raptures yesterday after publishing new data from its Phase 3 MIRASOL study of its drug ELAHERE, in patients with FRα-Positive, Platinum-Resistant Ovarian Cancer (“PROC”). Prior to yesterday’s news, ImmunoGen…

Gene sequencing at record speeds to identify dangerous mutations. A treatment that delays Type 1 diabetes for years. A vaccine to prevent RSV infections, which kill thousands of Americans each year. Below we describe these and other recent developments in academic medicine that could help save the lives of millions…

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our condensed consolidated financial statements and the related notes and other financial information included elsewhere in this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K for the…

Reports And Data The aquaculture vaccines market was USD 3.76 Billion in 2022 and is expected to register a rapid revenue CAGR of 8.40% during the forecast period The aquaculture vaccines market was USD 3.76 Billion in 2022 and is expected to register a rapid revenue CAGR of 8.40% during…

Vedanta Biosciences – a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia – announced that it has raised $106.5 million to support the pivotal-stage development of its lead candidate VE303 for the prevention of recurrent Clostridioides difficile infection (CDI), and a…

The “wildtype” RNA sequence contains numerous unpaired nucleotide loops, which leads to less stability. The LinearDesign algorithm generates sequences with significantly fewer loops, a more stable structure. Credit: Baidu Research A team of researchers from Baidu Research has developed an AI algorithm that can rapidly design highly stable COVID-19 mRNA…

Dublin, May 02, 2023 (GLOBE NEWSWIRE) — The “Enzymatic DNA Synthesis Market Forecast to 2028 – COVID-19 Impact and Global Analysis By Product Type, Application, End User, and Technology” report has been added to ResearchAndMarkets.com‘s offering. The enzymatic DNA synthesis market value is projected to reach US$ 2,244.88 million by…

On May 1, 2023, Pfizer and Astellas announced the release of detailed data from their Phase 3 EMBARK trial. The trial tested Xtandi in combination with leuprolide and as a monotherapy against a placebo plus leuprolide in men with non-metastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence. The companies reported…

MT Newswires 2023 All news about PFIZER, INC. Analyst Recommendations on PFIZER, INC. Sales 2023 68 816 M – – Net income 2023 15 837 M – – Net Debt 2023 778 M – – P/E ratio 2023 13,6x Yield 2023 4,28% Capitalization 220 B 220 B – EV / Sales 2023 3,20x…

Are you interested in pursuing a career in the rapidly expanding field of bioinformatics? If so, a Bachelor of Technology in Bioinformatics might be the perfect degree program for you. This interdisciplinary field combines computer science, biology, and mathematics to analyze biological data and solve complex problems related to genetics,…

TD Asset Management Inc has reduced its stake in Pfizer Inc by 3.6% during the fourth quarter, according to its recent filing with the Securities and Exchange Commission (SEC). The institutional investor held 8,979,485 shares of Pfizer’s stock after selling 334,841 shares during the period. TD Asset Management is believed…